Pulmonx Corporation logo

Pulmonx Corporation (LUNG)

Market Open
11 Sep, 14:09
NASDAQ (NGS) NASDAQ (NGS)
$
1. 84
-0.01
-0.5405%
$
87.85M Market Cap
- P/E Ratio
- Div Yield
49,334 Volume
-1.65 Eps
$ 1.85
Previous Close
Add Transaction
Day Range
1.84 2
Year Range
1.13 2.89
Want to track LUNG and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Pulmonx Corporation (LUNG) Q2 2024 Earnings Call Transcript

Pulmonx Corporation (LUNG) Q2 2024 Earnings Call Transcript

Pulmonx Corporation (NASDAQ:LUNG ) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Elizabeth Sparicio - Investor Relations Steve Williamson - President & Chief Executive Officer Mehul Joshi - Chief Financial Officer Conference Call Participants Jason Bednar - Piper Sandler John Young - Canaccord Frank Takkinen - Lake Street Capital Markets Operator Ladies and gentlemen, thank you for standing by. Welcome to the Pulmonx Second Quarter 2024 Earnings Conference Call.

Seekingalpha | 2 years ago
Pulmonx Corporation (LUNG) Reports Q2 Loss, Tops Revenue Estimates

Pulmonx Corporation (LUNG) Reports Q2 Loss, Tops Revenue Estimates

Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.43 per share a year ago.

Zacks | 2 years ago
Pulmonx: Low Bar For Q2 Earnings

Pulmonx: Low Bar For Q2 Earnings

New CEO suggests status quo with respect to corporate strategy. Upcoming Q2 earnings have low expectations, which could provide a short-term positive catalyst. However, longer-term, the main issue with Pulmonx remains the mismatch between revenues and expenses.

Seekingalpha | 2 years ago
How Much Upside is Left in Pulmonx (LUNG)? Wall Street Analysts Think 80.3%

How Much Upside is Left in Pulmonx (LUNG)? Wall Street Analysts Think 80.3%

The consensus price target hints at an 80.3% upside potential for Pulmonx (LUNG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks | 2 years ago